(Q45158949)

10 December 2017

title

Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas (English)

1 reference

10 December 2017

0 references

1

1 reference

10 December 2017

Salvatore Cardali

7

0 references

Francesca Granata

object named as

Francesca Granata

8

0 references

author name string

Antonio Pontoriero

2

1 reference

10 December 2017

Donatella Arpa

3

1 reference

10 December 2017

Carmelo Siragusa

4

1 reference

10 December 2017

Chiara Tomasello

5

1 reference

10 December 2017

Pantaleo Romanelli

6

1 reference

10 December 2017

Costantino De Renzis

9

1 reference

10 December 2017

Francesco Tomasello

10

1 reference

10 December 2017

publication date

9 October 2011

1 reference

10 December 2017

1 reference

10 December 2017

volume

154

1 reference

10 December 2017

issue

2

1 reference

10 December 2017

page(s)

203-209

1 reference

'Recurrent' glioblastoma multiforme, when should we reoperate?

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Survival and functional status after resection of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Protecting venous structures during radiosurgery for parasagittal meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Treatment options for recurrent glioblastoma: pitfalls and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Stereotactic radiosurgery for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Gamma knife for glioma: selection factors and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Reirradiation tolerance of the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protoco

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

New approaches for temozolomide therapy: use in newly diagnosed glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

New (alternative) temozolomide regimens for the treatment of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

Reoperation for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-011-1184-1

10.1007/S00701-011-1184-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

1043937683

0 references

1 reference